Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Income (2016 - 2025)

KalVista Pharmaceuticals' Operating Income history spans 11 years, with the latest figure at -$55.0 million for Q2 2025.

  • On a quarterly basis, Operating Income fell 13.57% to -$55.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$193.5 million, a 37.78% decrease, with the full-year FY2025 number at -$188.0 million, down 33.86% from a year prior.
  • Operating Income hit -$55.0 million in Q2 2025 for KalVista Pharmaceuticals, down from -$45.8 million in the prior quarter.
  • Over the last five years, Operating Income for KALV hit a ceiling of -$12.7 million in Q1 2021 and a floor of -$55.0 million in Q2 2025.
  • Historically, Operating Income has averaged -$37.3 million across 4 years, with a median of -$38.7 million in 2024.
  • Biggest five-year swings in Operating Income: grew 0.53% in 2021 and later crashed 54.01% in 2024.
  • Tracing KALV's Operating Income over 4 years: stood at -$12.7 million in 2021, then plummeted by 135.02% to -$29.7 million in 2023, then tumbled by 54.01% to -$45.8 million in 2024, then dropped by 20.12% to -$55.0 million in 2025.
  • Business Quant data shows Operating Income for KALV at -$55.0 million in Q2 2025, -$45.8 million in Q4 2024, and -$44.2 million in Q3 2024.